

Article

Not peer-reviewed version

A Novel Mechanism for Bone Loss: Platelet Count Negatively Correlates with Bone Mineral Density via Megakaryocyte-Derived RANKL

Shohei Kikuchi [†], [Akinori Wada](#) [†], Yusuke Kamihara, Imari Yamamoto, Daiki Kirigaya, Kohei Kunimoto, Ryusuke Horaguchi, Takuma Fujihira, Yoshimi Nabe, Tomoki Minemura, Nam H Dang, [And Tsutomu Sato](#) ^{*}

Posted Date: 5 July 2023

doi: 10.20944/preprints202307.0274.v1

Keywords: platelet; bone mineral density; megakaryocyte; RANKL



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

A Novel Mechanism for Bone Loss: Platelet Count Negatively Correlates with Bone Mineral Density via Megakaryocyte-Derived RANKL

Shohei Kikuchi ^{1†}, Akinori Wada ^{1†}, Yusuke Kamihara ¹, Imari Yamamoto ¹, Daiki Kirigaya ¹, Kohei Kunimoto ¹, Ryusuke Horaguchi ¹, Takuma Fujihira ¹, Yoshimi Nabe ¹, Tomoki Minemura ¹, Nam H. Dang ² and Tsutomu Sato ^{1*}

¹ Department of Hematology, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan; skikuchi@med.u-toyama.ac.jp (S.K.); akino@med.u-toyama.ac.jp (A.W.); kamihara@med.u-toyama.ac.jp (Y.K.); s1950100@ems.u-toyama.ac.jp (I.Y.); odahamak@med.u-toyama.ac.jp (D.K.); kunimoto@med.u-toyama.ac.jp (K.K.); rhora@med.u-toyama.ac.jp (R.H.); tfujihi@med.u-toyama.ac.jp (T.F.); yoshimitb20@gmail.com (Y.N.); tominemura@gmail.com (T.M.)

² Division of Hematology/Oncology, University of Florida, Gainesville, FL 32610, USA; namdang5@outlook.com

* Correspondence: tsutomus@med.u-toyama.ac.jp; Tel.: +81-76-434-7232

† These authors contributed equally to this work.

Abstract: A potential association between hematopoietic stem cell status in the bone marrow and the surrounding bone tissue has been hypothesized, and some studies have investigated the link between blood count and bone mineral density (BMD), although their exact relationship remains controversial. Moreover, biological factors linking the two are largely unknown. In our present study, we found no clear association between platelet count and BMD in the female group, with aging having a very strong effect on BMD. On the other hand, a significant negative correlation was found between platelet count and BMD in the male group. As a potential mechanism, we examined whether megakaryocytes, the source of platelet production, secrete cytokines that regulate BMD, namely OPG, M-CSF, and RANKL. We detected the production of these cytokines by megakaryocytes deriving from bone marrow mononuclear cells and found that RANKL was negatively correlated with BMD. This finding suggests that RANKL production by megakaryocytes may mediate the negative correlation between platelet count and BMD. To our knowledge, this is the first report to analyze bone marrow cells as a mechanism for the association between blood count and BMD. Our study may provide new insights into the development and potential treatment of osteoporosis.

Keywords: platelet; bone mineral density; megakaryocyte; RANKL

1. Introduction

Hematopoiesis is closely related to bone. The bone marrow fills small and irregular marrow cavities produced by mesh-like networks of trabeculae called spongy bones, which are surrounded by compact bones. The hematopoietic stem cells (HSC) then attach to osteoblasts in the endosteum on the inside of the compact bone and on the surface of the trabeculae, which is called the endosteal niche, a preferential site of residence for the most potent HSC [1]. Therefore, it is possible that a rich bone mass supports robust hematopoiesis, and studies have focused on the relationship between the number of white blood cells (WBC), red blood cells (RBC), and platelets (Plt), which reflect hematopoiesis, and bone mineral density (BMD). However, published work on the possible correlation between BMD and WBC, RBC, and particularly Plt levels have demonstrated conflicting results.

Several reports have shown a negative correlation between Plt count and BMD [2–4]. Kristjansdottir HL, et al. conducted an analysis of 1,005 men (median age 75.3 years, range 69–81) and found that the relationship between lumbar spine BMD (L1–L4) and Plt count was $r=-0.06$, $p=0.041$,

and that between total hip BMD and Plt count was $r=-0.11$, $p=0.003$ [2]. Kim J, et al. examined 8,634 subjects, including men over 50 years of age and postmenopausal women [4], and showed that in the highest Plt quartile, the odds ratio (95% confidence interval) of osteopenia vs. normal BMD was 1.39 (1.03-1.88), and that of osteoporosis vs. normal BMD was 1.60 (1.07-2.37). Furthermore, Li L, et al. analyzed 673 postmenopausal women and reported that the correlation between femur neck BMD and Plt count was $r = -0.153$, $p = 0.001$ [3]. Several hypotheses have been proposed for the potential mechanism responsible for the negative correlation between Plt count and BMD, including the involvement of serotonin [2], which is known to be negatively correlated with BMD [5] and is found in abundance in Plt [6].

On the other hand, there are published results that are not consistent with the findings above. Work by Valderrábano RJ, et al. [7,8]. The 2017 report included 2,571 men aged 65 years and older [7], and the 2019 report included 5,888 men and women also aged 65 years and older [8]. Meanwhile, other studies revealed a positive correlation between Plt count and BMD, with one by Schyrr F, et al. involving 143 patients prior to chemotherapy for breast cancer [9] and another by Kim HL, et al. involving 338 postmenopausal women [10].

Thus far, there has therefore been no definitive conclusion on the association between Plt count and BMD, nor has there been any analysis of the possible biological mechanism behind any reported association. In this paper, we demonstrate a negative correlation between BMD and Plt count in men, with women being strongly affected by age factors. We propose that the underlying biological mechanism may involve the receptor activator of nuclear factor-kappa B ligand (RANKL), which is secreted by megakaryocytes responsible for the production of platelets.

2. Results

2.1. Patient Characteristics

Table 1 presents the clinical characteristics of the 65 patients in our study (33 females and 32 males). There was no difference in age between men and women. All patients have malignant lymphomas, the majority of whom have the histologic type diffuse large B cell lymphoma (DLBCL). The proportion of patients with advanced disease (clinical stage III/IV) as compared to those with limited stage disease (clinical stage I/II) was higher in the female group than in the male group ($p=0.031$). For BMD, the female group was clearly lower than the male group for L2-L4, L1-L4, total hip, and femur neck ($p<0.001$). On the other hand, levels of WBC, neutrophils (Neu), lymphocytes (Lymph), RBC, hemoglobin (Hb), reticulocyte count (Ret), Plt, and tartrate-resistant acid phosphatase-5b (TRACP-5b), a marker of osteoclast number and bone resorption, showed no statistically significant difference between the sexes.

Table 1. Characteristics of the patients (n=65).

	Female (n=33)	Male (n=32)	p
Age (years)	73 (53-87)	72 (39-84)	0.449
DLBCL/Others	21/12	25/7	0.199
CS I, II/III, IV	18/15	9/23	0.031
L2-L4 BMD (g/m ²)	1.025±0.147	1.258±0.21	<0.001
L1-L4 BMD (g/m ²)	0.99±0.143	1.211±0.197	<0.001
Total hip BMD (g/m ²)	0.775±0.115	0.914±0.123	<0.001
Femur neck BMD (g/m ²)	0.724±0.113	0.852±0.107	<0.001
WBC (×10 ⁹ L)	6.2 (2.5-16.5)	6.8 (3.6-12.0)	0.335
Neu (×10 ⁹ L)	3.7 (1.1-14.1)	4.3 (1.8-9.7)	0.503
Lymph (×10 ⁹ L)	0.9 (0.3-1.6)	0.9 (0.2-1.7)	0.870
RBC (×10 ¹² L)	4.2 (2.4-5.0)	4.1 (2.8-5.4)	0.707
Hb (g/L)	122 (80-166)	125 (81-156)	0.798
Ret (×10 ⁹ L)	54 (29-150)	59 (33-130)	0.772
Plt (×10 ⁹ L)	246 (164-492)	258 (68-420)	0.644

TRACP-5b (mU/dL)	419±152	410±166	0.827
------------------	---------	---------	-------

2.2. Correlation between BMD and Plt Count

As shown in Table 2, all four BMDs decreased with age in the female group. TRACP-5b level was negatively correlated with BMD in L2-L4, L1-L4, and total hip. For CBC, positive correlations were observed between BMD and Lymph for L2-L4, L1-L4, and Total hip, but no correlation was observed between BMD and Plt. Results for the male group are presented in Table 3. BMD did not decrease with age; on the contrary, BMD in L2-L4 and L1-L4 increased with age. TRACP-5b level was negatively correlated with BMD in L1-L4 and total hip. Negative correlations were found between BMD and WBC and Neu in total hip and femur neck with respect to CBC. Negative correlations were also found between BMD and Plt for total hip and femur neck (both $r=-0.365$, $p=0.040$). Since the negative correlation between BMD and Plt was confirmed only in male patients, the sample of female patients was not included in the subsequent analyses.

Table 2. Spearman analysis between BMD and selected variables in female patients (n=33).

BMD	L2-L4		L1-L4		Total hip		Femur neck	
	r	P	r	P	r	P	r	P
Age	-0.283	0.022	-0.288	0.020	-0.491	<0.001	-0.576	<0.001
WBC	0.017	0.892	0.037	0.771	-0.012	0.927	-0.172	0.170
Neu	-0.087	0.492	-0.049	0.697	-0.126	0.316	-0.204	0.103
Lymph	0.257	0.039	0.254	0.041	0.263	0.034	0.040	0.752
RBC	0.046	0.715	0.004	0.975	-0.021	0.866	-0.076	0.545
Hb	-0.079	0.531	-0.129	0.306	-0.014	0.914	0.001	0.996
Ret	0.100	0.429	0.064	0.614	0.115	0.362	-0.065	0.606
Plt	0.169	0.354	0.165	0.376	-0.050	0.784	-0.079	0.667
TRACP-5b	-0.302	0.015	-0.302	0.014	-0.292	0.018	-0.022	0.862

Table 3. Spearman analysis between BMD and selected variables in male patients (n=32).

BMD	L2-L4		L1-L4		Total hip		Femur neck	
	r	P	r	P	r	P	r	P
Age	0.310	0.012	0.314	0.011	0.111	0.381	-0.047	0.709
WBC	-0.188	0.134	-0.208	0.096	-0.314	0.011	-0.324	0.008
Neu	-0.215	0.086	-0.236	0.059	-0.374	0.002	-0.328	0.008
Lymph	0.079	0.532	0.048	0.706	-0.009	0.941	-0.063	0.618
RBC	-0.168	0.182	-0.195	0.120	-0.055	0.666	-0.049	0.699
Hb	-0.053	0.673	-0.072	0.567	0.123	0.330	0.091	0.471
Ret	0.220	0.078	0.212	0.091	0.132	0.293	0.222	0.075
Plt	-0.254	0.160	-0.284	0.115	-0.365	0.040	-0.365	0.040
TRACP5b	-0.216	0.084	-0.250	0.045	-0.312	0.011	-0.214	0.087

2.3. Correlation between BMD and Megakaryocyte-Produced RANKL

To evaluate for potential biological mechanism involved in the observed negative correlation between Plt count and BMD, we focused on BMD regulators secreted by megakaryocytes (MGK), which are responsible for Plt production. Bone marrow mononuclear cells (BM-MNC) from male patients were induced to differentiate into MGK, and the production of RANKL, osteoprotegerin (OPG), and macrophage colony stimulating factor (M-CSF) were examined as BMD regulators (Table

4). MGK differentiation resulted in enhanced expression of CD41a, a marker of MGK (Figure 1). Importantly, we observed a negative correlation between RANKL and BMD in the femur neck ($r=-0.502$, $p=0.034$) (Table 4, Figure 2).




Figure 1. Megakaryocytic differentiation of BM-MNC. BM-MNC of patients were stimulated to differentiate into MGK. Megakaryocytic differentiation was estimated by the expression of CD41a using flow cytometric technique.




Figure 2. Correlation between BMD and RANKL-production of megakaryocytic-differentiated BM-MNC. Following stimulation of megakaryocytic-differentiation, production of RANKL in BM-MNC was estimated by quantitative real-time RT-PCR method and was analyzed for correlation with femur neck BMD.

Table 4. Spearman analysis between BMD and key OC factors in MGK of male patients (n=18).

BMD	L2-L4		L1-L4		Total hip		Femur neck	
	r	P	r	P	r	P	r	P
RANKL	-0.266	0.286	-0.330	0.181	-0.399	0.101	-0.502	0.034
OPG	-0.108	0.670	-0.138	0.586	-0.216	0.390	-0.425	0.079
M-CSF	-0.010	0.968	-0.013	0.958	-0.124	0.623	-0.056	0.827

3. Discussion

By excluding women and focusing only on men in our present study, we were able to find a negative correlation between Plt count and BMD. It is our assumption that such a correlation between Plt count and BMD is also present in women as well. However, since aging has an extremely potent effect on BMD in women (Table 2), it may be difficult to delineate the relationship between BMD and other factors, independent of age. It is likely that a factor linking aging to lower BMD in women is

lower level of estrogen [11,12], with age-related estrogen withdrawal in women leading to decreased BMD through a variety of mechanisms [13].

In the female group in our study, there was a positive correlation between BMD and Lymph count (Table 2), which may also be due to an estrogen effect. In a previous paper, it was reported that hormone replacement therapy with estrogen led to increased lymphocyte ratio in postmenopausal women [14]. Therefore, it is possible that aging lowers estrogen levels, resulting in lymphocytopenia.

When considering the potential biological mechanism involved in the negative correlation between Plt count and BMD in the male group, we focused on MGK, given the dependence of Plt production on MGK. In addition, previous work [15] demonstrated that increased MGK resulted in greater MGK-derived RANKL production, associated with higher level of osteoclasts in older mice than in younger mice. Since osteoclasts are responsible for BMD reduction, a factor linking increased Plt count with BMD reduction may be RANKL production by MGK. To evaluate this hypothesis, we examined the production of cytokines by MGK which can affect BMD, specifically RANKL, OPG, and M-CSF. RANKL and M-CSF induce osteoclast differentiation and decrease BMD, while OPG inhibits RANKL [16]. Our work revealed a negative correlation between RANKL production and BMD (Table 4) while level of TRACP-5b, an activation marker of osteoclasts induced to differentiate by RANKL and others, was negatively correlated with total hip BMD (Table 3).

Besides Plt count, a negative correlation with BMD was observed for WBC in the male group, especially Neu count (Table 3). This relationship between Neu count and BMD in a male cohort (n=2,571) was also reported by another group [7]. Specifically, femur neck BMD was lower in men with higher Neu counts than in men with lower Neu counts ($p=0.016$), and the decrease in total hip and femur neck BMD over time was greater ($p<0.001$). This observed phenomenon may also be due to the involvement of RANKL, since a relationship between RANKL production in peripheral neutrophils and BMD loss has been reported in 59 male patients with chronic obstructive pulmonary disease (COPD) [17].

In our study, the inverse association between Plt count and BMD was revealed by excluding women who are greatly affected by aging, associated with a decrease in estrogen. Searching for a potential biological mechanism, we focused on MGK, the source of platelet production, and found that MGK production of RANKL was inversely correlated with BMD. This meant that the production of platelets and RANKL by MGK was behind the inverse correlation between Plt count and BMD. However, there are limitations to our conclusion. Specifically, we did not formally examine the MGK population itself, but rather the MGK-like cells induced to differentiate from BM-MNCs. In the present study, we utilized BM-MNC isolated and cryopreserved from residual bone marrow samples as a retrospective analysis. These BM-MNC were then induced to differentiate into MGK, since BM-MNC isolated by the standard Ficoll purification method do not contain MGK. In the future, we plan to isolate MGK directly from fresh bone marrow samples as part of a prospective study to further confirm our present conclusions.

Furthermore, it may be difficult to fully analyze the role of bone marrow-derived cells in studies of human BMD, since BMD measurements and bone marrow aspiration tests are typically never conducted in the same time frame. One exception would be the pretreatment systemic search for disease involvement performed on patients diagnosed with malignant lymphoma. Bone marrow aspiration tests as part of the pretreatment staging studies are done to evaluate for potential bone marrow infiltration of lymphoma cells, and pretreatment BMD measurements are obtained as baseline levels, out of concern for exacerbation of osteoporosis caused by the corticosteroids that are included in standard anti-lymphoma therapies such as R-CHOP and others.

4. Materials and Methods

4.1. Patient Samples

Patients with malignant lymphoma who had bone density tests (dual-energy x-ray absorptiometry; DEXA) using PRODIGY (GE HealthCare) [18], blood tests for complete blood counts (CBC) and bone metabolism markers (tartrate-resistant acid phosphatase-5b; TRACP-5b), and bone marrow tests performed at the Department of Hematology, University of Toyama Hospital between

April 2019 and November 2021 were included. This study was conducted according to the Declaration of Helsinki and was approved by the ethics committees of Toyama University Hospital (reference number R2021127). Written informed consent was obtained from all patients prior to study participation.

4.2. Cell Culture

The method for inducing differentiation of bone marrow mononuclear cells (BM-MNC) into megakaryocytes (MGK) **was previously described** [19]. Lymphoprep™ (Serumwerk Bernburg AG) was used to isolate BM-MNC from bone marrow puncture fluid. Isolated BM-MNC were cultured in MegaCult™-C Medium with Cytokines (STEMCELL technologies) for 14 days. It contains the following: Iscove's Modified Dulbecco's Medium, bovine serum albumin, recombinant human (rh) insulin, human transferrin (iron-saturated), 2-Mercaptoethanol, rh thrombopoietin, rh interleukin (IL)-6, rh IL-3, and supplements.

4.3. Flow Cytometry

For flow cytometric analyses, samples were collected using a FACSCanto II flow cytometer (BD Biosciences) and analyzed with FlowJo software (Treestar). Expression of CD41a was analyzed using an FITC mouse anti-human CD41a, clone HIP8, antibody (BD Biosciences).

4.4. Quantitative Real-Time RT-PCR

Following stimulation for MGK-differentiation, BM-MNC were lysed and total RNA was extracted by the use of RNeasy Plus Mini Kit (QIAGEN) according to the manufacturer's instructions. Total RNA (1 µg) was reverse transcribed using QuantiTect Rev. Transcription Kit (QIAGEN). Quantification of mRNA was performed using the iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad) and QuantiTect SYBR Green PCR Kit (QIAGEN). Data obtained were analyzed with iQ™5 Optical System Software, Version 2.1 (Bio-Rad), being normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. The following PCR primers were designed: 5'-TGA GAC ACC TCT CCA GTT GCT G-3' and 5'-GCA ATC AGG CTT GGT CAC CAC A-3' for M-CSF; 5'-GGT CTC CTG CTA ACT CAG AAA GG-3' and 5'-CAG CAA ACC TGA AGA ATG CCT CC-3' for OPG; 5'-GCC TTT CAA GGA GCT GTG CAA AA-3' and 5'-GAG CAA AAG GCT GAG CTT CAA GC-3' for RANKL; 5'-GTC TCC TCT GAC TTC AAC AGC G-3' and 5'-ACC ACC CTG TTG CTG TAG CCA A-3' for GAPDH.

5. Conclusions

In this study, we investigated the association between CBC and BMD, and found that Plt count was a parameter demonstrating a negative correlation with BMD, especially in the total hip and femur neck regions of middle-aged and elderly men. We also demonstrated a negative correlation between RANKL production by MGK and BMD in the femur neck. These findings suggest that the negative correlation between Plt count and BMD may be mediated by RANKL production by MGK, which is responsible for Plt production. Our study provides new insights into RANKL production by MGK in osteoporosis and may have implications for the prevention and treatment of this disease.

Author Contributions: Investigation, methodology, S.K., A.W., Y.K., I.Y., D.K., K.K., R.H., T.F., Y.N., and T.M.; writing—review and editing, N.H.D.; funding acquisition, writing—original draft, T.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by Japan Science and Technology Agency (JST) Moonshot R&D Grant Number JPMJMS2021, Japan Agency for Medical Research and Development (AMED) Grant Number 21lm0203005j0005 (A145), 22ym0126807j0001 (A160), 21am0401024h0003, and Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research Grant Number 21K07237.

Institutional Review Board Statement: This study was approved by the ethics committees of Toyama University Hospital (reference number R2021127).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data are available on reasonable request. All data relevant to the study are included in the article.

Acknowledgments: We gratefully thank Toyomi Kozawa for her help in performing this study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Lévesque, J.P.; Helwani, F.M.; Winkler, I.G. The Endosteal Osteoblastic Niche and Its Role in Hematopoietic Stem Cell Homing and Mobilization. *Leukemia* **2010**, *24*, 1979–1992, doi:10.1038/leu.2010.214.
2. Kristjansdottir, H.L.; Mellström, D.; Johansson, P.; Karlsson, M.; Vandenput, L.; Lorentzon, M.; Herlitz, H.; Ohlsson, C.; Lerner, U.H.; Lewerin, C. High Platelet Count Is Associated with Low Bone Mineral Density: The MrOS Sweden Cohort. *Osteoporosis International* **2021**, *32*, 865–871, doi:10.1007/s00198-020-05766-6.
3. Li, L.; Ge, J.R.; Chen, J.; Ye, Y.J.; Xu, P.C.; Li, J.Y. Association of Bone Mineral Density with Peripheral Blood Cell Counts and Hemoglobin in Chinese Postmenopausal Women: A Retrospective Study. *Medicine* **2020**, *99*, e20906, doi:10.1097/MD.00000000000020906.
4. Kim, J.; Kim, H.S.; Lee, H.S.; Kwon, Y.J. The Relationship between Platelet Count and Bone Mineral Density: Results from Two Independent Population-Based Studies. *Arch Osteoporos* **2020**, *15*, 43, doi:10.1007/s11657-020-0700-4.
5. Mödder, U.I.; Achenbach, S.J.; Amin, S.; Riggs, B.L.; Melton, L.J.; Khosla, S. Relation of Serum Serotonin Levels to Bone Density and Structural Parameters in Women. *Journal of Bone and Mineral Research* **2010**, *25*, 415–422, doi:10.1359/jbmr.090721.
6. Bader, M. Inhibition of Serotonin Synthesis: A Novel Therapeutic Paradigm. *Pharmacol Ther* **2020**, *205*, 107423, doi:10.1016/j.pharmthera.2019.107423.
7. Valderrábano, R.J.; Lui, L.Y.; Lee, J.; Cummings, S.R.; Orwoll, E.S.; Hoffman, A.R.; Wu, J.Y. Bone Density Loss Is Associated With Blood Cell Counts. *Journal of Bone and Mineral Research* **2017**, *32*, 212–220, doi:10.1002/jbmr.3000.
8. Valderrábano, R.J.; Buzkova, P.; Chang, P.Y.; Zakai, N.A.; Fink, H.A.; Robbins, J.A.; Lee, J.S.; Wu, J.Y. Association of Bone Mineral Density with Hemoglobin and Change in Hemoglobin among Older Men and Women: The Cardiovascular Health Study. *Bone* **2019**, *120*, 321–326, doi:10.1016/j.bone.2018.11.010.
9. Schyrr, F.; Wolfer, A.; Pasquier, J.; Nicoulaz, A.L.; Lamy, O.; Naveiras, O. Correlation Study between Osteoporosis and Hematopoiesis in the Context of Adjuvant Chemotherapy for Breast Cancer. *Ann Hematol* **2018**, *97*, 309–317, doi:10.1007/s00277-017-3184-6.
10. Kim, H.L.; Cho, H.Y.; Park, I.Y.; Choi, J.M.; Kim, M.; Jang, H.J.; Hwang, S.M. The Positive Association between Peripheral Blood Cell Counts and Bone Mineral Density in Postmenopausal Women. *Yonsei Med J* **2011**, *52*, 739–745, doi:10.3349/ymj.2011.52.5.739.
11. Cauley, J.A. Estrogen and Bone Health in Men and Women. *Steroids* **2015**, *99*, 11–15, doi:10.1016/j.steroids.2014.12.010.
12. Levin, V.A.; Jiang, X.; Kagan, R. Estrogen Therapy for Osteoporosis in the Modern Era. *Osteoporosis International* **2018**, *29*, 1049–1055, doi:10.1007/s00198-018-4414-z.
13. Li, J.; Chen, X.; Lu, L.; Yu, X. The Relationship between Bone Marrow Adipose Tissue and Bone Metabolism in Postmenopausal Osteoporosis. *Cytokine Growth Factor Rev* **2020**, *52*, 88–98, doi:10.1016/j.cytogfr.2020.02.003.
14. Kamada, M.; Irahara, M.; Maegawa, M.; Yasui, T.; Takeji, T.; Yamada, M.; Tezuka, M.; Kasai, Y.; Aono, T. Effect of Hormone Replacement Therapy on Post-Menopausal Changes of Lymphocytes and T Cell Subsets. *J Endocrinol Invest* **2000**, *23*, 376–382, doi:10.1007/BF03343741.
15. Kanagasabapathy D; Blosser RJ; Maupin KA; Hong JM; Alvarez M; Ghosh J; Mohamad SF; Aguilar-Perez A; Srouf EF; Kacena MA; et al. Megakaryocytes Promote Osteoclastogenesis in Aging. *Aging (Albany NY)* **2020**, *12*, 15121–15133.
16. Kandahari, A.M.; Yang, X.; Laroche, K.A.; Dighe, A.S.; Pan, D.; Cui, Q. A Review of UHMWPE Wear-Induced Osteolysis: The Role for Early Detection of the Immune Response. *Bone Res* **2016**, *4*, doi:10.1038/boneres.2016.14.
17. Hu, X.L.; Sun, Y.; Xu, W.; Lin, T.; Zeng, H. Expression of RANKL by Peripheral Neutrophils and Its Association with Bone Mineral Density in COPD. *Respirology* **2017**, *22*, 126–132, doi:10.1111/resp.12878.

18. Hull, H.; He, Q.; Thornton, J.; Javed, F.; Allen, L.; Wang, J.; Pierson, R.N.; Gallagher, D. IDXA, Prodigy, and DPXL Dual-Energy X-Ray Absorptiometry Whole-Body Scans: A Cross-Calibration Study. *Journal of Clinical Densitometry* **2009**, *12*, 95–102, doi:10.1016/j.jocd.2008.09.004.
19. Faulhaber, M.; Wörmann, B.; Ganser, A.; Verbeek, W. In Vitro Response of Myelodysplastic Megakaryocytopoiesis to Megakaryocyte Growth and Development Factor (MGDF). *Ann Hematol* **2002**, *81*, 695–700, doi:10.1007/s00277-002-0540-x.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.